Extended-Release Amantadine for Levodopa-Induced Dyskinesia

References

• Voon V, Napier TC, Frank MJ, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson’s disease: an update. Lancet Neurol. 2017;16(3):238–250.
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa‐induced dyskinesias. Mov Disord. 2007;22(10):1379–1389.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Tanner CM, Hauser RA, et al. ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial. JAMA Neurol. 2017;74(8):941–949.
   PubMed Web of Science ®Google Scholar
• Espay AJ, Morgante F, Merola A, et al. Levodopa‐induced dyskinesia in Parkinson disease: current and evolving concepts. Ann Neurol. 2018;84(6):797–811.
   PubMed Web of Science ®Google Scholar
• Vijayakumar D, Jankovic JJD. Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia. Drugs. 2016;76(7):759–777.
   PubMed Web of Science ®Google Scholar
• Luquin M, Scipioni O, Vaamonde J, et al. Levodopa‐induced dyskinesias in Parkinson’s disease: clinical and pharmacological classification. Mov Disord. 1992;7(2):117–124.
   PubMed Web of Science ®Google Scholar
• Fahn S. Levodopa in the treatment of Parkinson’s disease. J Neural Transm Suppl. 2006;71(1):1–15.
   PubMedGoogle Scholar
• Obeso J, Stamelou M, Goetz C, et al. Past, present, and future of Parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy. Mov Disord. 2017;32(9):1264–1310.
   PubMed Web of Science ®Google Scholar
• Benabid AL. Deep brain stimulation for Parkinson’s disease. Curr Opin Neurobiol. 2003;13(6):696–706.
   PubMed Web of Science ®Google Scholar
• Benabid AL, Chabardes S, Mitrofanis J, et al. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurol. 2009;8(1):67–81.
   PubMed Web of Science ®Google Scholar
• Yianni A, Aziz T. Surgical treatment of Parkinson’s disease. Adv Clin Neruosci Rehabil 1997;2(6):21-22.
   Google Scholar
• Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2006;355(9):896–908.
   PubMed Web of Science ®Google Scholar
• Koch G, Brusa L, Caltagirone C, et al. rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease. Neurology. 2005;65(4):623–625.
   PubMed Web of Science ®Google Scholar
• Koch G, Oliveri M, Brusa L, et al. High-frequency rTMS improves time perception in Parkinson disease. Neurology. 2004;63(12):2405–2406.
   PubMed Web of Science ®Google Scholar
• Lefaucheur J-P, André-Obadia N, Antal A, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol. 2014;125(11):2150–2206.
   PubMed Web of Science ®Google Scholar
• Pacifici G, Nardini M, Ferrari P, et al. Effect of amantadine on drug‐induced parkisonism: relationship between plasma levels and effect. Br J Clin Pharmacol. 1976;3(5):883–889.
   PubMed Web of Science ®Google Scholar
• Vernier VG, Harmon JB, Stump JM, et al. The toxicologic and pharmacologic properties of amantadine hydrochloride. Toxicol Appl Pharmacol. 1969;15(3):642–665.
   PubMed Web of Science ®Google Scholar
• Schwab RS, England AC, Poskanzer DC, et al. Amantadine in the treatment of Parkinson’s disease. JAMA. 1969;208(7):1168–1170.
   Google Scholar
• Shukla AW. Extended-release amantadine—a smart pill for treatment of levodopa-induced dyskinesia but does the evidence justify the cost? JAMA Neurol. 2017;74(8):904–905.
   PubMed Web of Science ®Google Scholar
• Hauser R, Pahwa R, Wargin W, et al. Pharmacokinetics of ADS-5102 (amantadine) extended release capsules administered once-daily at bedtime for the treatment of dyskinesia. Clin Pharmacokinet. 2019;58(1):77-88.
   Google Scholar
• Oertel W, Eggert K, Pahwa R, et al. Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson’s disease (EASE LID 3). Mov Disord. 2017;32(12):1701–1709.
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence‐based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018;33(8):1248-1266.
   Google Scholar
• Pahwa R, Tanner CM, Hauser RA, et al. Amantadine extended release for levodopa‐induced dyskinesia in Parkinson’s disease (EASED Study). Mov Disord. 2015;30(6):788–795.
   PubMed Web of Science ®Google Scholar
• Thomas A, Iacono D, Luciano A, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75(1):141–143.
   PubMed Web of Science ®Google Scholar
• Hickey P, Stacy M. Adenosine A2A antagonists in Parkinson’s disease: what’s next? Curr Neurol Neurosci Rep. 2012;12(4):376–385.
   PubMed Web of Science ®Google Scholar
• Sako W, Murakami N, Motohama K, et al. The effect of istradefylline for Parkinson’s disease: a meta-analysis. Sci Rep. 2017;7(1):18018.
   PubMedGoogle Scholar
• Kumar R, Hauser RA, Mostillo J, et al. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson’s disease patients. Int J Neurosci. 2016;126(1):20–24.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Stocchi F, Poewe W, et al. Mavoglurant in Parkinson’s patients with l‐dopa‐induced dyskinesias: two randomized phase 2 studies. Mov Disord. 2016;31(7):1054–1058.
   PubMed Web of Science ®Google Scholar
• Du -J-J, Chen S-D. Current nondopaminergic therapeutic options for motor symptoms of Parkinson’s. Chin Med J (Engl). 2017;130(15):1856.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–149.
   PubMed Web of Science ®Google Scholar
• Antonini A, Poewe W, Chaudhuri KR, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Parkinsonism Relat Disord. 2017; 45:13–20.
   Google Scholar
• Pierelli F, Adipietro A, Soldati G, et al. Low dosage clozapine effects on L‐dopa induced dyskinesias in parkinsonian patients. Acta Neurol Scand. 1998;97(5):295–299.
   PubMed Web of Science ®Google Scholar
• Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology. 2004;62(3):381–388.
   PubMed Web of Science ®Google Scholar
• Greulich W, Fenger E. Amantadine in Parkinson’s disease: pro and contra. J Neural Transm Supplementum. 1995;46:415–421.
   PubMedGoogle Scholar
• Stocchi F. The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations. Expert Opin Pharmacother. 2006;7(10):1399–1407.
   PubMedGoogle Scholar
• Stathis P, Konitsiotis S, Tagaris G, et al. Levetiracetam for the management of levodopa‐induced dyskinesias in Parkinson’s disease. Mov Disord. 2011;26(2):264–270.
   PubMed Web of Science ®Google Scholar
• Wolz M, Löhle M, Strecker K, et al. Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. J Neural Transm. 2010;117(11):1279–1286.
   PubMed Web of Science ®Google Scholar
• Vertical Pharmaceuticals L. Osmolex ER Package Insert. Bridgewater, NJ; 2018:1–16.
   Google Scholar
• Bazil C, Crouse E, Dalton V, et al. Osmolex ER - another extended-release amantadine for Parkinson’s disease. Med Lett Drugs Ther. 2018;60(1555):148–150.
   PubMed Web of Science ®Google Scholar
• Administration USFaD. Prescribing Information: GOCOVRI. Silver Spring, MD; 2017.
   Google Scholar
• Dashtipour K, Chung JS, Wu AD, et al. "Chapter 18: Amantadine and anticholinergics. Handbook of Parkinson’s disease. Ed. Rajesh Pahwa, Ed. Kelly Lyons. Boca Raton: CRC Press, 2013. 373-388. Print.
   Google Scholar
• Pharmaceuticals A. GOCOVRI (amantadine extended release capsules) [package insert]. Emeryville, CA; 2018.
   Google Scholar
• Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet. 1988;14(1):35–51.
   PubMed Web of Science ®Google Scholar
• Deeter R, Khanderia U. Recent advances in antiviral therapy. Clin Pharm. 1986;5(12):961–976.
   PubMedGoogle Scholar
• Fahn S, Craddock G, Kumin G. Acute toxic psychosis from suicidal overdosage of amantadine. Arch Neurol. 1971;25(1):45–48.
   PubMedGoogle Scholar
• Farnebo L-O, Fuxe K, Goldstein M, et al. Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson’s disease. Eur J Pharmacol. 1971;16(1):27–38.
   PubMed Web of Science ®Google Scholar
• Wilson T, Rajput A. Amantadine-dyazide interaction. Can Med Assoc J. 1983;129(9):974.
   PubMed Web of Science ®Google Scholar
• Thomas A, Bonanni L, Gambi F, et al. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010;68(3):400–404.
   PubMed Web of Science ®Google Scholar
• Trappler B, Miyashiro AM. Bupropion-amantadine-associated neurotoxicity. J Clin Psychiatry. 2000;61(1):61.
   PubMed Web of Science ®Google Scholar
• Factor SA, Molho ES. Transient benefit of amantadine in Parkinson’s disease: the facts about the myth. Mov Disord. 1999;14(3):515–517.
   PubMed Web of Science ®Google Scholar
• Kaefer V, Semedo JG, Kahl S, et al. DNA damage in brain cells and behavioral deficits in mice after treatment with high doses of amantadine. J appl toxicol. 2010;30(8):745–753.
   PubMed Web of Science ®Google Scholar
• Snyder RD, Green JW. A review of the genotoxicity of marketed pharmaceuticals. Mutat Res/Rev Mutat Res. 2001;488(2):151–169.
   PubMed Web of Science ®Google Scholar
• Cowan BD, Lucas JA, Sopelak VM, et al. Failed fertilization during an in vitro fertilization cycle after oral ingestion of amantadine hydrochloride. J in Vitro Fertilization Embryo Transfer. 1988;5(5):282–285.
   PubMedGoogle Scholar
• Disorders MDS TFoR SfPsDJM. The unified Parkinson’s disease rating scale (UPDRS): status and recommendations. Mov Disord. 2003;18(7):738–750.
   PubMed Web of Science ®Google Scholar
• Hoops S, Nazem S, Siderowf A, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73(21):1738–1745.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Nutt JG, Stebbins G. The unified dyskinesia rating scale: presentation and clinimetric profile. Mov Disord. 2008;23(16):2398–2403.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Pahwa R, Tanner CM, et al. ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 2 Study): interim results of an open-label safety study. J Parkinsons Dis. 2017;7(3):511–522.
   PubMedGoogle Scholar
• Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord. 2005;20(2):224–230.
   PubMed Web of Science ®Google Scholar